
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9465350/publications.pdf Version: 2024-02-01



ΔΙΔΝΚ ΠΑΥΙς

#	Article	IF	CITATIONS
1	Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia. Journal of Psychoactive Drugs, 2023, 55, 73-84.	1.7	7
2	Effects of Psychedelic Use on Racial Trauma Symptoms and Ethnic Identity among Asians in North America. Journal of Psychoactive Drugs, 2023, 55, 19-29.	1.7	8
3	The acceptability of non-abstinent treatment goals among clinical social workers in the United States. Journal of Social Work Practice, 2023, 37, 339-354.	1.0	1
4	The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology, 2022, 36, 309-320.	4.0	34
5	Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal of Psychoactive Drugs, 2022, 54, 309-318.	1.7	26
6	Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans. Journal of Psychedelic Studies, 2022, 5, 149-155.	1.2	7
7	Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 2022, 36, 151-158.	4.0	162
8	Implementing traumatic brain injury screening in behavioral healthcare: protocol for a prospective mixed methods study. Implementation Science Communications, 2022, 3, 17.	2.2	2
9	Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019. , 2022, 2, .		3
10	Applying Lessons From Cannabis to the Psychedelic Highway. JAMA Health Forum, 2022, 3, e221618.	2.2	11
11	A randomized controlled trial of social media interventions for risky drinking among adolescents and emerging adults. Drug and Alcohol Dependence, 2022, 237, 109532.	3.2	7
12	A quadripartite model of passion for marijuana use: associations with consumption, consequences, craving, and satisfaction with life. Addiction Research and Theory, 2021, 29, 30-35.	1.9	5
13	Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 481.	11.0	648
14	People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs: Education, Prevention and Policy, 2021, 28, 215-226.	1.3	45
15	Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. Journal of Psychopharmacology, 2021, 35, 437-446.	4.0	79
16	Developing Your Program's Substance Misuse Minor/Concentration. Journal of Social Work Practice in the Addictions, 2021, 21, 202-206.	0.7	0
17	Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects. ACS Pharmacology and Translational Science, 2021, 4, 424-435.	4.9	109
18	Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacology and Translational Science, 2021, 4, 543-552.	4.9	58

#	Article	IF	CITATIONS
19	Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 569.	11.0	1
20	Examining Same-Day Associations Between Cannabis Use Motives and Condom Use in Urban Emerging Adults: A Brief Report. Journal of Studies on Alcohol and Drugs, 2021, 82, 516-521.	1.0	1
21	What undergraduates want in campus sexual assault prevention programming: Findings from a formative research study. Journal of American College Health, 2021, , 1-8.	1.5	0
22	Ketamine-assisted psychotherapy for trauma-exposed patients in an outpatient setting: A clinical chart review study. Journal of Psychedelic Studies, 2021, 5, 94-102.	1.2	4
23	Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color. Chronic Stress, 2021, 5, 247054702110356.	3.4	19
24	Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 2021, 11, 574.	4.8	115
25	Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Current Topics in Behavioral Neurosciences, 2021, , 1.	1.7	2
26	Evaluation of the dualistic model of passion for alcohol consumption among emerging adults engaged in risky drinking. Addiction Research and Theory, 2020, 28, 21-28.	1.9	4
27	Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science, 2020, 15, 39-45.	2.6	172
28	Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology, 2020, 237, 773-785.	3.1	61
29	Acceptance of Non-Abstinence as an Outcome Goal for Individuals Diagnosed With Substance Use Disorders: A Narrative Review of Published Research. Journal of Studies on Alcohol and Drugs, 2020, 81, 405-415.	1.0	22
30	A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. Journal of Psychoactive Drugs, 2020, 52, 289-299.	1.7	89
31	Long-term effects of psychedelic drugs: A systematic review. Neuroscience and Biobehavioral Reviews, 2020, 113, 179-189.	6.1	96
32	Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects. Journal of Psychoactive Drugs, 2020, 52, 273-281.	1.7	20
33	Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic Stress, 2020, 4, 247054702093956.	3.4	37
34	Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. Journal of Psychedelic Studies, 2020, 4, 114-122.	1.2	14
35	Survey of entity encounter experiences occasioned by inhaled <i>N,N</i> -dimethyltryptamine: Phenomenology, interpretation, and enduring effects. Journal of Psychopharmacology, 2020, 34, 1008-1020.	4.0	64
36	Acceptance of Non-Abstinence as an Outcome Goal for Individuals Diagnosed With Substance Use Disorders: A Narrative Review of Published Research. Journal of Studies on Alcohol and Drugs, 2020, 81, 405-415.	1.0	3

ALAN K DAVIS

#	Article	IF	CITATIONS
37	Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 2019, 33, 1088-1101.	4.0	145
38	Predictors of empirically derived substance use patterns among sexual minority groups presenting at an emergency department. Addictive Behaviors, 2019, 96, 76-81.	3.0	6
39	Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE, 2019, 14, e0214377.	2.5	132
40	5-methoxy- <i>N,N</i> -dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. American Journal of Drug and Alcohol Abuse, 2019, 45, 161-169.	2.1	91
41	Passion for Marijuana Use Mediates the Relations between Refusal Self-Efficacy and Marijuana Use and Associated Consequences. Journal of Psychoactive Drugs, 2019, 51, 343-350.	1.7	3
42	Individual and Social Factors Related to Trajectories of Blackouts among Underage Drinkers in the Emergency Department. Alcohol and Alcoholism, 2019, 54, 370-377.	1.6	4
43	Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Frontiers in Psychiatry, 2019, 10, 955.	2.6	75
44	Veterans with recent substance use and aggression: PTSD, substance use, and social network behaviors Psychological Trauma: Theory, Research, Practice, and Policy, 2019, 11, 424-433.	2.1	8
45	The epidemiology of 5-methoxy- <i>N, N</i> -dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Journal of Psychopharmacology, 2018, 32, 779-792.	4.0	84
46	Factors associated with alcohol consumption among medical cannabis patients with chronic pain. Addictive Behaviors, 2018, 77, 166-171.	3.0	15
47	Recent cannabis use among Veterans in the United States: Results from a national sample. Addictive Behaviors, 2018, 76, 223-228.	3.0	41
48	Prevalence and motives for drugged driving among emerging adults presenting to an emergency department. Addictive Behaviors, 2018, 78, 80-84.	3.0	18
49	Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. Frontiers in Psychology, 2018, 9, 2459.	2.1	54
50	Substance use consequences, mental health problems, and readiness to change among Veterans seeking substance use treatment. Journal of Substance Abuse Treatment, 2018, 94, 113-121.	2.8	12
51	Predictors of positive drinking outcomes among youth receiving an alcohol brief intervention in the emergency department. Drug and Alcohol Dependence, 2018, 188, 102-108.	3.2	11
52	A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification. Journal of Psychoactive Drugs, 2018, 50, 287-297.	1.7	16
53	Dual Trajectories of Depression/Anxiety Symptoms and Alcohol Use, and their Implications for Violence Outcomes Among Drug-Using Urban Youth. Alcohol and Alcoholism, 2018, 53, 659-666.	1.6	9
54	Acceptability of nonabstinent treatment outcome goals among addiction treatment providers in Ukraine Psychology of Addictive Behaviors, 2018, 32, 485-495.	2.1	5

#	Article	IF	CITATIONS
55	Why do young people consume marijuana? Extending motivational theory via the dualistic model of passion Translational Issues in Psychological Science, 2018, 4, 54-64.	1.0	10
56	Binge-drinking and non-partner aggression are associated with gambling among Veterans with recent substance use in VA outpatient treatment. Addictive Behaviors, 2017, 74, 27-32.	3.0	8
57	The Dualistic Model of Passion applied to recreational marijuana consumption. Addiction Research and Theory, 2017, 25, 188-194.	1.9	6
58	Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ ecstasy users in the United States and the United Kingdom. Drug Science, Policy and Law, 2017, 3, 205032451771106.	1.3	16
59	Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. Journal of Psychedelic Studies, 2017, 1, 65-73.	1.2	30
60	American counselors' acceptance of non-abstinence outcome goals for clients diagnosed with co-occurring substance use and other psychiatric disorders. Journal of Substance Abuse Treatment, 2017, 82, 29-33.	2.8	26
61	Psychometric Evaluation of the Work Acceptance and Action Questionnaire of Psychological Flexibility Modified for University Students. Journal of College Student Development, 2017, 58, 1256-1260.	0.9	Ο
62	Factors associated with having a medical marijuana card among Veterans with recent substance use in VA outpatient treatment. Addictive Behaviors, 2016, 63, 132-136.	3.0	22
63	Patterns of Use, Acute Subjective Experiences, and Motivations for Using Synthetic Cathinones ("Bath) Tj ET	Qq1,1 0.7	84314 rgBT /(
64	Attitudes and Beliefs About the Acceptability and Justness of Peer Victimization of Lesbian and Gay University Students. Journal of Homosexuality, 2016, 63, 808-820.	2.0	4
65	Acceptability of Non-Abstinence Goals among Students Enrolled in Addiction Studies Programs across the United States. Substance Abuse, 2016, 37, 204-208.	2.3	10
66	Using the Theory of Planned Behavior to predict implementation of harm reduction strategies among MDMA/ecstasy users Psychology of Addictive Behaviors, 2016, 30, 500-508.	2.1	20
67	Self-Medication of Somatic and Psychiatric Conditions Using Botanical Marijuana. Journal of Psychoactive Drugs, 2015, 47, 345-350.	1.7	41
68	Application of the Passionate Attachment Model to Recreational Use of MDMA/Ecstasy. Journal of Psychoactive Drugs, 2015, 47, 24-29.	1.7	12
69	The Prevalence, Intensity, and Assessment of Craving for MDMA/Ecstasy in Recreational Users. Journal of Psychoactive Drugs, 2014, 46, 154-161.	1.7	14
70	Psychometric evaluation of the Marijuana Reduction Strategies Self-Efficacy Scale with young recreational marijuana users. Addictive Behaviors, 2014, 39, 1750-1754.	3.0	8
71	Differences in the acceptability of non-abstinence goals by type of drug among American substance abuse clinicians. Journal of Substance Abuse Treatment, 2014, 46, 214-218.	2.8	30
72	Development and evaluation of the Marijuana Reduction Strategies Self-Efficacy Scale Psychology of Addictive Behaviors, 2014, 28, 575-579.	2.1	12

#	Article	IF	CITATIONS
73	Evaluation of the criterion and predictive validity of the Alcohol Reduction Strategies—Current Confidence (ARS-CC) in a natural drinking environment. Addictive Behaviors, 2013, 38, 1940-1943.	3.0	3
74	Acceptance of non-abstinence goals by addiction professionals in the United States Psychology of Addictive Behaviors, 2013, 27, 1102-1109.	2.1	81
75	Examining Perceived Stereotype Threat among Overweight/Obese Adults Using a Multi-Threat Framework. Obesity Facts, 2013, 6, 258-268.	3.4	14